作者
Piervito Lopriore,Zeynep Ünlütürk,T Klopstock,Amel Karaa,Cécile Rouzier,Cristina Domínguez-González,Costanza Lamperti,Michelangelo Mancuso,Giulia Cecchi,Vincenzo Montano,Gabriele Siciliano,Valeria Nicoletta,Mariantonietta Maioli,Guido Primiano,S. Servidei,Chiara La Morgia,Valerio Carelli,Maria Lucia Valentino,Leonardo Caporali,Ignazio Giuseppe Arena
摘要
BACKGROUND AND OBJECTIVES: gene, is a mitochondrial DNA helicase that unwinds the double helix of DNA during replication, playing a pivotal role in mitochondrial function. Twinkle-related disorders encompass a variety of genetic disorders characterized by mitochondrial dysfunction. Although several phenotypes have been described, the full clinical and molecular spectrum remains poorly defined. The aim of this study was to characterize the phenotypic and genotypic variability among multinational patients diagnosed with Twinkle-related disorders. METHODS: A retrospective cohort study was conducted in patients with Twinkle-related disorders at several specialized centers in Italy, France, Germany, Spain, Denmark, Hungary, and the United States, establishing the Twinkle-Related Disorders International Consortium for Trial Readiness (TReDIC). Data were collected from medical records, including clinical features, age at onset, disease progression, and results from genetic testing. Phenotypic categories included infantile-onset cerebellar ataxia, parkinsonism, primary mitochondrial myopathy (PMM), multisystem involvement, asymptomatic carriers, undetermined phenotypes, and other phenotypes. All patients' diagnoses were confirmed by genetic analysis, and their genetic variants were noted. Outcomes included prevalence of phenotypes, symptom chronology, and mutational patterns. RESULTS: variants (16 novel) were found, mostly missense, clustered in functionally critical regions. DISCUSSION: This large multinational cohort analysis advances our understanding of Twinkle-related disorders by identifying mutational hotspots with clinical relevance and illustrating the broad phenotypic spectrum and progression patterns. In the context of such rare diseases, the formation of international collaborations, such as TReDIC, can enhance our understanding and support the design of upcoming clinical trials.